BIOMARKER COMPOSITION FOR DETERMINING CANCER DRUG RESPONSIVENESS, METHOD FOR DETERMINING CANCER DRUG RESPONSIVENESS USING BIOMARKER COMPOSITION, AND DIAGNOSTIC CHIP FOR DETECTING BIOMARKER COMPOSITION FOR DETERMINING CANCER DRUG RESPONSIVENESS

摘要

The present invention relates to a biomarker composition for determining the responsiveness of a discovered cancer drug by using genetic biomarker labeling scan (GBLscan), which is a drug indication and responsiveness prediction system and method, as a new learning model capable of reliably predicting the responsiveness of a drug by performing coupling analysis on a molecular profile of the drug after transforming specific genetic variation fingerprints related to diseases including cancer into a haplotype having functional information, a method for determining cancer drug responsiveness using the biomarker composition, and a diagnostic chip for detecting a biomarker composition for determining cancer drug responsiveness.